Video shots
Dr Enrique Grande, Dr Alison Birtle, Dr Axel Merseburger and Dr Petros Grivas talk through the data presented at ESMO 2024 and discuss their insights on how the disclosures may affect future treatment options and individualized sequencing for mUC patients.
Enrique Grande and Alison Birtle talk through their interpretations of the disitamab vedotin in HER2-high patients, EV-302 and nectin-4, CheckMate901 and HRQoL, and Javelin Bladder 100 trial data from ESMO 2024.
Enrique Grande and Alison Birtle discuss the AMBASSADOR, SunRISe-1, NIAGARA, and VOLGA trial data from onsite at ESMO 2024 and what it may mean for future practice.
Axel Merseburger and Petros Grivas go into a deeper dive on the presidential presentation of the NIAGARA data at ESMO 2024 and how it may affect optimal treatment sequencing in mUC.
